Patient Guide: A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 16 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06577025
Status: 🟢 Enrolling Now
Condition: Multiple Myeloma, Neoplasms, Plasma Cell
Phase: PHASE2

Where You Can Participate

This study is available at 16 locations across the country.

Top locations include:
  • • Duarte, California
  • • San Francisco, California
  • • Iowa City, Iowa
  • • And 13 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma - Join Clinical Trial NCTNCT06577025

How to Join This Clinical Trial - NCTNCT06577025

Learn how to participate in this PHASE2 trial studying an investigational therapy for Multiple Myeloma, Neoplasms, Plasma Cell. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Multiple Myeloma, Neoplasms, Plasma Cell. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Multiple Myeloma, Neoplasms, Plasma Cell
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06577025 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 16 locations. Find a study site near you:

Clinical Research Site

Duarte, California 91010 - United States

Status: RECRUITING

Clinical Research Site

San Francisco, California 94143 - United States

Status: RECRUITING

Clinical Research Site

Iowa City, Iowa 52242 - United States

Status: RECRUITING

Clinical Research Site

New York, New York 10065 - United States

Status: RECRUITING

Clinical Research Site

Charlotte, North Carolina 28204 - United States

Status: RECRUITING

Clinical Research Site

Melbourne, 3000 - Australia

Status: ACTIVE_NOT_RECRUITING

Clinical Research Site

Melbourne, 3004 - Australia

Status: ACTIVE_NOT_RECRUITING

Clinical Research Site

Salvador, 41253 190 - Brazil

Status: RECRUITING

Clinical Research Site

Sao Paulo, 01509 900 - Brazil

Status: RECRUITING

Clinical Research Site

Sao Paulo, 05652 900 - Brazil

Status: RECRUITING

And 6 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for Multiple Myeloma, Neoplasms, Plasma Cell:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships